These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36922032)

  • 21. Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review.
    Desai H; Al-Salihi MM; Morsi RZ; Vayani OR; Kothari SA; Thind S; Carrión-Penagos J; Baskaran A; Tarabichi A; Bonderski VA; Siegler JE; Hahn M; Coleman ER; Brorson JR; Mendelson SJ; Mansour A; Dabus G; Hurley M; Prabhakaran S; Linfante I; Kass-Hout T
    Front Neurol; 2023; 14():1304599. PubMed ID: 38116108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet Therapy During Emergent Extracranial Internal Carotid Artery Stenting: Comparison of Three Intravenous Antiplatelet Perioperative Strategies.
    Delvoye F; Maier B; Escalard S; Labreuche J; Thion LA; Aknouche S; Hebert S; Redjem H; Smajda S; Ciccio G; Allard J; Sabben C; Obadia M; Maertens de Noordhout A; Olivot JM; Blanc R; Piotin M; Desilles JP; Mazighi M
    J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105521. PubMed ID: 33310073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of intravenous cangrelor and stenting in acute ischemic stroke interventions: a new single center analysis and pooled-analysis of current studies.
    Paul AR; Entezami P; Holden D; Field N; Dalfino J; Boulos A
    Interv Neuroradiol; 2021 Dec; 27(6):837-842. PubMed ID: 33945341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.
    Nakamura M; Kadota K; Takahashi A; Kanda J; Anzai H; Ishii Y; Shibata Y; Yasaka Y; Takamisawa I; Yamaguchi J; Takeda Y; Harada A; Motohashi T; Iijima R; Uemura S; Murakami Y;
    J Am Heart Assoc; 2020 May; 9(10):e015439. PubMed ID: 32394794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis.
    Vargas D; Zhou H; Yu X; Diamond S; Yeh J; Allada V; Krishnamurthy G; Price M; Allen B; Alexander J; Schmidhofer J; Kreutzer J; Vincent J; Morell V; Bacha E; Diacovo T
    J Thromb Haemost; 2021 Jan; 19(1):202-211. PubMed ID: 33078501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
    Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
    J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between silent embolic cerebral infarction and continuous increase of P2Y12 reaction units after neurovascular stenting.
    Kim BJ; Kwon JY; Jung JM; Lee DH; Kang DW; Kim JS; Kwon SU
    J Neurosurg; 2014 Oct; 121(4):891-8. PubMed ID: 25036195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
    Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
    Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet Function Testing to Guide Cangrelor Dosing in Patients with Temporary Mechanical Circulatory Support or as a Bridge to Procedure.
    Buck MM; Barry CI; Montepara CA; Verlinden NJ
    Clin Appl Thromb Hemost; 2024; 30():10760296241237228. PubMed ID: 38439661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review.
    Salgia A; Krueger CK; Gillette MA
    Ann Pharmacother; 2023 May; 57(5):544-552. PubMed ID: 36004393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cangrelor: A Review in Percutaneous Coronary Intervention.
    Keating GM
    Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.